Comparative Pharmacology
Head-to-head clinical analysis: DIVALPROEX SODIUM versus TRIDIONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIVALPROEX SODIUM versus TRIDIONE.
DIVALPROEX SODIUM vs TRIDIONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases brain concentrations of gamma-aminobutyric acid (GABA), blocks voltage-gated sodium channels, and modulates T-type calcium channels.
Increases seizure threshold by modulating voltage-gated sodium channels and enhancing GABA-ergic inhibition.
10-15 mg/kg/day orally in divided doses; increase by 5-10 mg/kg/week; maximum 60 mg/kg/day. Extended-release: 25 mg/kg/day orally; increase by 15 mg/kg/day at weekly intervals; maximum 60 mg/kg/day.
300-600 mg orally three times daily; titrate to seizure control.
None Documented
None Documented
9-16 hours (terminal); shorter in children (6-9 hours) and longer in hepatic disease or elderly; clinical context: twice-daily dosing provides stable trough concentrations.
16-24 hours (trimethadione); dimethadione (active metabolite) has a half-life of ~6-12 days, leading to drug accumulation.
Renal: <3% unchanged; primarily hepatic metabolism (glucuronidation, beta-oxidation, cytochrome P450), metabolites eliminated renally; fecal: negligible.
Renal: ~70% as unchanged drug and metabolites (including dimethadione); biliary/fecal: minimal (<10%).
Category D/X
Category C
Anticonvulsant
Anticonvulsant